CompletedPhase 2NCT03715946

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Studying Squamous cell carcinoma of the oropharynx

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Robert L. Ferris, MD, PhD
Principal Investigator
Robert Ferris, MD, PhD
UPMC Hillman Cancer Center
Intervention
Nivolumab Injection(drug)
Enrollment
40 target
Eligibility
18 years · All sexes
Timeline
20182024

Study locations (3)

Collaborators

Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03715946 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of the oropharynx

Additional recruiting or active studies for the same condition.

See all trials for Squamous cell carcinoma of the oropharynx

← Back to all trials